BMS buys rights to PRM-151 and Promedior
August 31, 2015
Bristol-Myers Squibb has bought rights to a fibrosis drug and its privately held developer - Promedior. The deal gives Bristol-Myers access to Promedior Inc's lead experimental drug, PRM-151, which is being tested in myelofibrosis as well as diopathic pulmonary fibrosis.
Promedior's mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.